Pharming Group N.V. (PHAR) has positioned itself at the center of rare disease innovation, with momentum building across its commercial portfolio and pipeline. The company's focus on hereditary angioedema (HAE) and activated PI3K delta syndrome (APDS) continues to generate growth, while upcoming regulatory milestones could expand its reach into new patient populations. RUCONEST Maintains Strength in HAE RUCONEST remains a cornerstone in the acute HAE market, supported by new patient enrolments and an expanding prescriber base. Even with the introduction of a new oral on-demand therapy in July, RUCONEST has sustained performance, underscoring its relevance in a competitive landscape. Joenja Expands APDS Reach Joenja (leniolisib) delivered significant revenue growth, driven by a 25% year-over-year increase in patients on paid therapy and consistently high adherence rates. Looking ahead, Pharming anticipates further uptake among APDS patients aged 12 and older, with additional growth expected from pediatric label expansion, reclassification of variants of uncertain significance, and regulatory approvals in major markets. Pipeline Progress Pharming's pipeline is advancing with potential new indications for leniolisib in broader primary immunodeficiency populations. The pivotal FALCON study for KL1333 in mitochondrial DNA-driven primary mitochondrial disease is also underway, targeting a significant unmet need. These programs highlight the company's ambition to broaden its rare disease portfolio. Pediatric Label Expansion A supplemental New Drug Application for leniolisib in children aged 4 to 11 years with APDS has been accepted by the FDA, with a Priority Review and a PDUFA target action date of January 31, 2026. A commercial launch is planned for the first quarter of 2026, pending approval. In parallel, a Phase III trial in children aged 1 to 6 has completed enrollment, with results expected soon. Financial Highlights Pharming reported a third-quarter profit of $7.5 million, reversing a loss of $1.1 million last year. Revenues rose 30% to $97.3 million, supported by strong product performance. Cash and cash equivalents increased to $168.9 million, reflecting $32 million in operating cash flow. The company also announced a reduction in general and administrative headcount to prioritize capital deployment toward high-growth initiatives. Stock Performance We profiled PHAR on July 12, 2024, when it was trading around $9.00. The stock reached an all-time high of $17.76 on November 10, 2025, representing a gain of over 97% from our published price.
Shares closed at $16.11 on November 19, up 1.19% during the session, before rising further to $16.60 in after-hours trading, a gain of 3.04%. Trading volume was 16,965 shares versus an average volume of 14,720 shares. Bottom Line Pharming Group's combination of commercial strength, advancing pipeline, and upcoming regulatory decisions makes it a stock to watch in the rare disease space. With RUCONEST holding ground, Joenja expanding its reach, and KL1333 progressing through pivotal trials, the company is approaching a period where execution on multiple fronts could significantly shape its trajectory.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.